chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Developed shingles in nose the next day which got progressively worse.  The doctor thought that I had a staph infection until the culture came back and he immediately stated that I had shingles.  Started on Valtrex(1gm)three times a day and had relief from the extreme pain in one day, but still have to recover from lesions.For 21 Caplets it cost $271.00 and I have medicare supplement insurance.  No where on you reactions to the vaccine does it suggest that it might bring on a shingles episode.  The last outbreak that I had was 40 years ago.
pt recv vax 2AUG95 & 7NOV95 pt presented in MD office w/a rash on trunk, arm, & head & an upper resp infect;pt recovered from exp;
pt recv vax 13OCT97 & 14OCT97 pt lt arm red, hot, painful from shoulder to elbow;limited rod-MD visit prescribed pred x 1 wk;15OCT97 condition worse-return to MD WBC 14,000 per mom;dx cellulitis;
I couldn't move my arm; Hurting all the way into my shoulder blade; This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (I couldn't move my arm) and ARTHRALGIA (Hurting all the way into my shoulder blade) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced LIMB DISCOMFORT (I couldn't move my arm) and ARTHRALGIA (Hurting all the way into my shoulder blade). At the time of the report, LIMB DISCOMFORT (I couldn't move my arm) and ARTHRALGIA (Hurting all the way into my shoulder blade) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were provided No Treatment information provided
DIARRHEA; FLU-LIKE SYMPTOMS; HEADACHE; NAUSEA; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 04-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 04-APR-2021, the subject experienced headache. On 04-APR-2021, the subject experienced nausea. On an unspecified date, the subject experienced diarrhea, and flu-like symptoms. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from headache, and the outcome of nausea, diarrhea and flu-like symptoms was not reported. This report was non-serious.
Swelling on leg, fever, excessive sleeping, high pitched crying episodes lasting over 2 hrs @ a time reluctant feeding.
development of Cruetzfeldt-Jakobs Disease; This is a spontaneous report from a contactable consumer. A 67-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via unspecified route in right arm on Mar2021 at 10:00 AM at patient age of 67-year-old as single dose for COVID-19 immunisation. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had no known allergies. The patient medical history and concomitant medication was none. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via unspecified route in right arm on Mar2021 at 10:00 AM at patient age of 67-year-old as single dose for COVID-19 immunisation. The patient experienced development of Cruetzfeldt-Jakobs Disease in May2021. The event resulted in Doctor or other healthcare professional office/clinic visit, Disability or permanent damage. It was unknown if patient received treatment. The patient has not been tested for COVID-19 post vaccination. The outcome of the event was not recovered.     The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
itching sensation to my whole body; tried to wear gloves to work and I broke out in welts (temporary)/ random hives on my body; still sick/could not physically sign forms; felt a burning sensation; pins and needles sensation; Dermatographic urticaria; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MECHANICAL URTICARIA (Dermatographic urticaria), PAIN IN EXTREMITY (Sore arm), PRURITUS (itching sensation to my whole body), URTICARIA (tried to wear gloves to work and I broke out in welts (temporary)/ random hives on my body) and ILLNESS (still sick/could not physically sign forms) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 18-Jan-2021 at 9:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MECHANICAL URTICARIA (Dermatographic urticaria), PAIN IN EXTREMITY (Sore arm), PRURITUS (itching sensation to my whole body), URTICARIA (tried to wear gloves to work and I broke out in welts (temporary)/ random hives on my body), ILLNESS (still sick/could not physically sign forms), BURNING SENSATION (felt a burning sensation) and PARAESTHESIA (pins and needles sensation). At the time of the report, MECHANICAL URTICARIA (Dermatographic urticaria), PRURITUS (itching sensation to my whole body), BURNING SENSATION (felt a burning sensation) and PARAESTHESIA (pins and needles sensation) outcome was unknown, PAIN IN EXTREMITY (Sore arm) had resolved and URTICARIA (tried to wear gloves to work and I broke out in welts (temporary)/ random hives on my body) and ILLNESS (still sick/could not physically sign forms) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2021, Histamine level: elevated (High) Elevated.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product information was not provided. Second dose was received on 15 Feb 2021 at 09:00.  Treatment information included Antihistamines.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: ADR form was attached on 15-JUN-2021, second dose details were added. On 12-Jul-2021: Follow-up received on 12-JUL-2021 contains no new information. On 12-Jul-2021: Follow up received on 12-jul-2021 contains Added New event still sick.
10 minutes after getting vaccine I had a heart rate of 122 just sitting in a chair. Went to a separate observation room. Heart rate went up to 132. Oxygen level was 97 or higher the whole time. Felt a little shaky. Nurse said I was flush and a little blotchy. Heart rate went down to 84 and went back up to 115 then went down and stayed down. I felt hot initially.
red spot around the injection site the size of a nickel; Diarrhea on and off; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea on and off) and VACCINATION SITE ERYTHEMA (red spot around the injection site the size of a nickel) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, the patient experienced DIARRHOEA (Diarrhea on and off). On 26-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (red spot around the injection site the size of a nickel). At the time of the report, DIARRHOEA (Diarrhea on and off) and VACCINATION SITE ERYTHEMA (red spot around the injection site the size of a nickel) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient reported that they take concomitant medicines for the heart and for blood pressure.   Treatment information was not provided.
Pt states recvd J & J vaccine 3/7/22 on left arm at Rite-Aid (Lot# 1855194). Pt reports "burning" chest discomfort the day after and regularly since 3/8/22. Pt is new with no prior cardiac disease. Pt denies SOB and left arm pain. Pt rates pain 4/10 and stable at that pain level.
About 3-4 weeks after the second Moderna vaccine, I developed shingles on my right torso. It was a fairly mild- moderate rash with a lot of pain in the area. The rash itself lasted about 2 weeks.  The pain and itching lasted longer.
The day of the vaccine, which was administered in the right deltoid, she developed localized soreness, which has persisted for the past 2 months.  The vaccine was given on 10/28/07.  She still has pain and some weakness of the proximal musculature of the right upper extremity.  Worse at night and in the morning.
Pain at left upper arm and shoulder area when patient moves the arm above head or behind the back. Also experiences numbness in same location along with pain. These symptoms last about 2 minutes then resolve per the patient. Symptoms started about 2 days post vaccination. Patient has not received any formal treatment.
Pt developed extreme crying for 48 hrs. She had 3 minutes of tonic clonic seizures 26 hrs after shots. She had decreased activity and eating for 4 days.
Fever of 102 lasted over 24 hours, irritable, did not sleep well. Rash on diaper area. Large red welp at vaccine site on leg.
pt states she received the second Shingrix vaccine on 11/12/19 in the Left Deltoid.  She states she had the same arm soreness and a bit of redness exactly like the first vaccine. However, with this dose on 11/13/19 her back started itching and her husband verified a pinpoint rash all over her back with what looked like tiny blisters.  This is on her legs as well but nowhere around the injection site.   She did not want to come in for me to look at it and she did not want to go to a physician to look at is as i recommended.
During routine chart audits found that Lot number for HIB was invalid. Later determined that lot number belonged to diluent that was part of our stock. Unable to determine if child received actual vaccine.
Diagnosed with shingles on my lower right rib cage, one week after shot. Vaccinated against shingles in 2019. Two doses. My 95-year-old mother received the COVID-19 booster the same day, same lot number. She also contracted shingles (on her lower right rib cage).
all over strong body aches, strong headache, fever @5 am= 100.8, mild intermittent nausea, chills,severe arm soreness at injection site...
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Mar-2021 at 2:33 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 20-Mar-2021 at 2:33 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 68.70 for dose administered on 20-Mar-2021  No concomitant medications were reported. Batch number 031A21A underwent temperature excursion on 20-Mar-2021 with temperature 37 degrees Fahrenheit from 02:00 PM to 03:00 PM. This vial was moved to fridge on 09-Mar-2021 and beyond use date for the vial was reported as 08-Apr-2021. Product moved to clinic on 20-Mar-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour. No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
Patient received  first Pfizer covid vaccine, has multiple allergies and was being kept for 30mins post to monitor for reactions. About 10 minutes after receiving vaccine patient complained of feeling of throat closing and coughing. At 9:24am epi pen was administered due to anaphylactic reaction.. Patient was put on a nonrebreather mask and then transitioned to 2L NC. Heart rate was 163 and SpO2 was 97%. Unable to get blood pressure as patient was shaking. Patient was transported by EMS to closest hospital.
fainting; Severe head, neck and back pain; Severe head, neck and back pain; Severe head, neck and back pain; nausea; vomiting; This is a spontaneous report from a contactable consumer, the patient. This 67-year-old non-pregnant female patient reported that she received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8737) via an unspecified route in the right arm on 19Apr2021 at 14:45 (at the age of 67-years-old) as a single dose for COVID-19 immunization. Medical history included chronic severe tension headaches and allergies to some antibiotics (unspecified products). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not have COVID prior to vaccination. Concomitant medications included unspecified supplements and herbals. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EP7534) on 27Mar2021 at 14:45 in the right arm as a single dose for COVID-19 immunization. On 20Apr2021 at 02:30, the patient experienced severe head, neck and back pain, combined with nausea, vomiting and fainting. There was no treatment received for severe head, neck and back pain, combined with nausea, vomiting and fainting. The clinical outcomes of severe head, neck and back pain, nausea, vomiting and fainting was recovering. The patient was not tested for COVID post vaccination.
Narrative:  Patient received first dose on 2/8/21. On 2/19/21 patient sent a secure message to PCP notifying him that she had a "terrible reaction to the Shingles vaccination last week." She states she was seen at a walk-in click and was prescribed doxycycline for 7 days but her arm rash was still "spreading and itching black and blue". Left arm WNL as of 4/5/21, but patient hesitant to receive 2nd dose of vaccine. Pt declined 2nd dose on 7/6/21. As of 8/17/21, it has not be addressed by PCP whether or not the patient should receive the 2nd dose.
After administration of covid vaccine, patient complained of "feeling dizzy". Offered to take patient to ER, she refused.  After 52 minutes, patient felt dizziness was mild and left facility.
Localized rxn with swelling, pain and redness. Mild cellulitis Rx cephalexin and mupirocin.
Swelling/redness around injection site and in the arm of injection. Started 2 days after injection.
one-sided moderate tinnitus; This is a spontaneous report received from a contactable physician. The physician reporting for a patient (son) that a male patient of unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunisation. Medical history was none. Concomitant medications were not reported. The physician reported that patient started experiencing one-sided moderate tinnitus one day after receiving vaccine. In searching, it likes like 0.6% of people experience this. Please advise on the appropriate treatment. Outcome of the event was unknown.   No follow-up attempts are needed. Information about lot/Batch number cannot be obtained.
Patient received a bivalent booster dose as a first dose; No adverse event; This spontaneous case was reported by a nurse and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received a bivalent booster dose as a first dose) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (Patient received a bivalent booster dose as a first dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient received a bivalent booster dose as a first dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient received a bivalent booster dose as a first dose).    No concomitant medications were reported. No treatment medications were reported.
pt recv vax & devel stiffness, droopy one side of the month x 5;no fever;sent to ER;
FLUMIST administered on 9/24/12, on 9/27/12 fever 105.5.
23yo G1P0 at 38+4 presents to L&d with n/v/d since 0400 3/23. Reports +COVID exposure. Denies SOB. +intermittent chest pain, sharp, goes away on its own. No SOB. Intermittent uterine cramping, no contractions, no LOF, no vaginal bleeding, no DFM. No headaches, vision changes, RUQ pain.
Patient received immunization 04/25/2003 developed redness and swelling on left leg at injection site.  No fever.  Is able to bear fall weight on left leg.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 07-APR-2016, the patient was vaccinated with an improperly stored dose of PROQUAD (injection, lot # L044058, expiration date 02-MAY-2017) (dose and route were not reported). Concomitant therapies were not provided. According to the reporter, the vaccine was stored at a temperature of 9.9 degrees Fahrenheit for 163 hours and 30 minutes. There was no previous temperature excursion reported. No adverse effect was reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Cellulitis around injection site; A spontaneous report was received from a healthcare professional, who is a 30-year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced cellulitis around injection site.  The patient's medical history was not provided. Concomitant medications were not reported.  On 31 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number: 011J20A), intramuscularly for prophylaxis of COVID-19 infection.  On 31 Dec 2020, a couple of hours after vaccination, the patient experienced cellulitis around the injection site. Her arm was hot and so painful that even when her clothes lightly touched or slid down on the injection site, she felt excruciating pain. She visited five different urgent cares but was rejected because the event was not considered high risk. No treatment information was provided.  Action taken with mRNA-1273 in response to the event was not reported.  The outcome of the event, cellulitis around injection site, was unknown.; Reporter's Comments: This case concerns a 30 year old, female who experienced a serious unexpected event of cellulitis. The event occurred same day after first dose of mRNA-1273 (Lot# 011J20A) administration. The subject concomitant and treatment medications were not provided. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
SLOW IMPROVEMENTS STARTED FEELING TINGLING IN HER TOES LIKE NERVES WERE COMING BACK TO LIFE AND ALMOST BACK TO NORMAL AS GO FOR WALKS AGAIN VACCINE WAS ABLE TO DO A RESET ON IMMUNE SYSTEM; This spontaneous report received from a parent via a company representative concerned a 22 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included red/purple toes, swollen toes, blistered toes, scaly toes, and painful toes, and other pre-existing medical conditions included patient suffered for a solid year with what was referred to as covid toes and her toes couldn't bend and looked like they had frostbite half the time. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on APR-2021 for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On an unspecified date, the subject experienced slow improvements started feeling tingling in her toes like nerves were coming back to life and almost back to normal as go for walks again vaccine was able to do a reset on immune system. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of slow improvements started feeling tingling in her toes like nerves were coming back to life and almost back to normal as go for walks again vaccine was able to do a reset on immune system was not reported. This report was non-serious.
This is a spontaneous report from a contactable consumer (the patient). A 56-year-old female patient received first dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, solution for injection, batch/lot# not reported), via an unspecified route of administration, on Mar 24, 2021, single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. In Mar 2021, patient experienced body ache, headache and fever. She had her 1st shot of the Pfizer COVID-19 vaccine on Mar 24, 2021; and experienced headache and body ache. She wanted to know if this was normal and how long it will last. The outcome of the events: unknown. No follow-up attempts possible. Information about lot/batch number cannot be obtained.
Felt vaccine go into arm. Arm was sore for a few days much like shots he had had in the past. Two weeks following the shot his arm worsened and he could not sleep on his left side and could not raise his arm. He needed help to get dressed it hurt so bad. He rated his pain at its worse a 10. He went to his general doctor and he could not diagnose the problem and sent him to an orthopedic doctor. The orthopedic doctor told him his muscle just needed to work it out. Today he rates his pain a 2 or 3.